{"Clinical Trial ID": "NCT00046891", "Intervention": ["INTERVENTION 1:", "Ginkgo Biloba", "Ginkgo Biloba: Patients take 120 mg daily (60 mg BID)", "INTERVENTION 2:", "- Placebo", "Placebo: patients will take 1 tablet BID"], "Eligibility": ["CHARACTERISTICS OF DISEASE:", "New breast cancer", "Intended standard dose of adjuvant chemotherapy with or without taxane", "CHARACTERISTICS OF PATIENTS:", "Age", "- 18 years and over", "Gender", "Women", "Status of menopause", "Any status", "State of play", "Eastern Cooperative Oncology Group (ECOG) 0-1", "Life expectancy", "At least 6 months", "Haematopoietic", "No haemorrhagic diathesis", "Hepatic", "- Serum glutamate oxaloacetate transaminase (SGOT) does not exceed 1.5 times the upper limit of normal (ULN)", "ALKALINE phosphatase not more than 1.5 times LSN", "Renal", "- Creatinine not exceeding 1.5 times ULN", "Cardiovascular disorders", "No arterial vascular disease", "Other", "\u2022 Capable of completing questionnaires alone or with assistance", "No diabetes", "No dementia", "No diagnosis of psychiatric disorder in the last 5 years that would prevent compliance with the study", "No other significant co-morbidity", "No known allergies to ginkgo biloba", "No pregnancy or breast-feeding", "Negative pregnancy test", "Fertile patients should use effective contraception", "THERAPE PRIOR CONCURENT:", "Biological therapy", "No concomitant stem cell transplantation", "- Chemotherapy", "No concomitant high-dose chemotherapy", "Other", "More than 6 months since previous EGb761", "No concomitant antithrombotic therapy (e.g., daily aspirin or anticoagulants)", "\u2022 Anticoagulants used for the maintenance of central or peripheral lines (i.e. warfarin 1 mg/day or heparin) authorized", "No concomitant dosing regimen", "No concomitant aspirin or aspirin-like medicinal products (e.g., indomethacin, ibuprofen, or certain antihistamines, heparin or warfarin [except those used above])", "No concomitant therapy should cause thrombocytopenia", "No trazodone, monoamine oxidase inhibitors or concomitant thiazide diuretics (e.g. chlorothiazide, hydrochlorothiazide, indapamide or metolazone)"], "Results": ["Performance measures:", "The level of cognitive dysfunction measured by the overall score of the High Sensitivity Cognitive Screen (HCCS).", "The primary analysis included the compilation of each subscale score for HSCS in the curve area (AUC) for base data points at the 12-month data point. The HSCS instrument contains questions about memory (0-39), language (0-30), visual motor (0-10), space (0-8), attention and concentration (0-25), self-regulation and planning (0-6) on variable scales.", "Timeline: Baseline, 12 months after the start of chemotherapy.", "Results 1:", "Title of the arm/group: Ginkgo Biloba", "Description of the arm/group: Ginkgo Biloba: Patients will take 120 mg daily (60 mg BID)", "Total number of participants analysed: 107", "Average (standard deviation)", "Unit of measurement: units on a scale*month Memory: 12.2 (9.18)", "Language: 3.9 (6.84)", "Visual engine: 1.1 (1.29)", "Space: 1.4 (0.92)", "Attention/concentration: 2.2 (3.59)", "Self-regulation: 2.4 (2.14)", "Total: 20.7 (19.59)", "Results 2:", "Title of the arm/group: Placebo", "Description of the arm/group: Placebo: Patients will take 1 tablet BID", "Total number of participants analysed: 103", "Average (standard deviation)", "Unit of measure: units on a scale*month Memory: 12,6 (9,16)", "Language: 2.6 (2.72)", "Visual engine: 0.7 (0.84)", "SPACE: 1.3 (0.92)", "Attention/concentration: 1.8 (2,16)", "Self-regulation: 2.0 (2.10)", "Total: 18.0 (12.26)"], "Adverse Events": ["Undesirable Events 1:", "Total: 4/104 (3.85 per cent)", "Febrile neutropenia 0/104 (0.00 %)", "Infection with neutropenia grade 3 or 4 1/104 (0.96%)", "Decrease in leukocyte count 1/104 (0.96%)", "- Decrease in the number of neutrophils 4/104 (3.85%)", "Decrease in platelet count 1/104 (0.96%)", "Adverse Events 2:", "Total: 3/101 (2.97 per cent)", "Febrile neutropenia 1/101 (0.99%)", "Infection with neutropenia grade 3 or 4 0/101 (0.00 %)", "Decrease in leukocyte count 2/101 (1.98%)", "Decrease in neutrophil count 2/101 (1.98%)", "Decrease in platelet count 0/101 (0.00 %)"]}